Focus Partners Wealth
NBIX icon

Focus Partners Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Focus Partners Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6M Buy
80,335
+10,401
+15% +$1.38M 0.01% 703
2025
Q4 		$9.92M Buy
69,934
+4,112
+6% +$596K 0.01% 697
2025
Q3 		$9.24M Buy
65,822
+8,645
+15% +$1.17M 0.01% 578
2025
Q2 		$7.19M Buy
57,177
+6,786
+13% +$778K 0.02% 572
2025
Q1 		$5.57M Sell
50,391
-687
-1% -$87K 0.01% 595
2024
Q4 		$6.97M Buy
51,078
+4,420
+9% +$547K 0.02% 542
2024
Q3 		$5.38M Buy
46,658
+782
+2% +$107K 0.02% 544
2024
Q2 		$6.32M Buy
45,876
+397
+0.9% +$54.4K 0.02% 457
2024
Q1 		$6.27M Buy
45,479
+5,058
+13% +$691K 0.05% 281
2023
Q4 		$5.33M Buy
+40,421
New +$4.65M 0.07% 224

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Focus Partners Wealth's NBIX Position: Q1 2026 in Review

Focus Partners Wealth increased its Neurocrine Biosciences (NBIX) stake by 15% in Q1 2026, buying an estimated $1.38M and bringing the position to 80,335 shares worth $10.6M. The position accounts for 0.01% of the portfolio, ranked #703.

Focus Partners Wealth first reported a position in NBIX in Q4 2023 and has held it in 10 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Focus Partners Wealth held 80,335 shares of Neurocrine Biosciences worth $10.6M as of Q1 2026.
  • Focus Partners Wealth bought 10,401 Neurocrine Biosciences shares in Q1 2026, an estimated $1.38M.
  • Neurocrine Biosciences made up 0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #703 holding.
  • Focus Partners Wealth first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 10 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.